8221. Rilmazafone
Nomenclature
CAS number: 99593-25-6
5-[[(Aminoacetyl)amino]methyl]-1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-N,N-dimethyl-1H-1,2,4-triazole-3-carboxamide; 1-(2-o-chlorobenzoyl-4-chlorophenyl)-5-glycylaminomethyl-3-dimethylcarbamoyl-1H-1,2,4-triazole; 2′,5-dichloro-2-(3-dimethylcarbamoyl-5-glycylaminomethyl-1H-1,2,4-triazol-1-yl)benzophenone. C21H20Cl2N6O3; mol wt 475.33.
C 53.06%, H 4.24%, Cl 14.92%, N 17.68%, O 10.10%.
Description and references
Ring-opened triazolobenzodiazepine derivative. Prepn: K. Hirai, H. Sugimoto, DE 2725164; eidem, US 4159374 (1977, 1979 both to Shionogi); and CNS activity: K. Hirai et al., J. Heterocycl. Chem. 19, 1363 (1982). Receptor binding study of rilmazafone and its closed ring active metabolites: M. Fujimoto et al., Biochem. Pharmacol. 33, 1645 (1984). Combined HPLC determn and enzyme immunoassay in plasma: G. Kominami et al., J. Chromatogr. 417, 216 (1987). Series of articles on teratogenicity studies: Oyo Yakuri 30, 749-833 (1985), C.A. 104, 81885h-81887k; 102328w (1986).
Derivative
Monohydrochloride dihydrate.Nomenclature
450191-S; Rhythmy (Shionogi).C21H20Cl2N6O3.HCl.2H2O; mol wt 547.82.
C 46.04%, H 4.60%, Cl 19.41%, N 15.34%, O 14.60%.
Properties
Solid from 95% ethanol, mp 107°. LD50 orally in mice: >1500 mg/kg (Hirai, 1979).Therapeutic Category
Sedative, hypnotic.
Keywords
Sedative/Hypnotic